Abstract
The N-methyl-D-aspartate (NMDA)-subtype of glutamate receptors has been well described as a result of the early appearance of NMDA antagonists, but no potent antagonist for the "non-NMDA" glutamate receptors has been available. Quinoxalinediones have now been found to be potent and competitive antagonists at non-NMDA glutamate receptors. These compounds will be useful in the determination of the structure-activity relations of quisqualate and kainate receptors and the role of such receptors in synaptic transmission in the mammalian brain.
MeSH terms
-
6-Cyano-7-nitroquinoxaline-2,3-dione
-
Action Potentials / drug effects
-
Animals
-
Aspartic Acid / analogs & derivatives
-
Aspartic Acid / pharmacology
-
Binding, Competitive
-
Cell Membrane / metabolism
-
Cerebral Cortex / metabolism
-
Ibotenic Acid / analogs & derivatives
-
Ibotenic Acid / metabolism
-
Kainic Acid / metabolism
-
Ketamine / pharmacology
-
N-Methylaspartate
-
Neurons / physiology
-
Piperazines / metabolism
-
Quinoxalines / pharmacology*
-
Rats
-
Receptors, AMPA
-
Receptors, Drug / drug effects
-
Receptors, Drug / metabolism
-
Receptors, Glutamate
-
Receptors, Kainic Acid
-
Receptors, N-Methyl-D-Aspartate
-
Receptors, Neurotransmitter / drug effects*
-
Receptors, Neurotransmitter / metabolism
-
Spinal Cord / physiology
-
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Substances
-
Piperazines
-
Quinoxalines
-
Receptors, AMPA
-
Receptors, Drug
-
Receptors, Glutamate
-
Receptors, Kainic Acid
-
Receptors, N-Methyl-D-Aspartate
-
Receptors, Neurotransmitter
-
Ibotenic Acid
-
Aspartic Acid
-
FG 9041
-
N-Methylaspartate
-
Ketamine
-
6-Cyano-7-nitroquinoxaline-2,3-dione
-
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
-
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
-
Kainic Acid